Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.22.2.2
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Basic and diluted numerator:    
Net loss attributable to iBio, Inc. $ (7,537) $ (5,188)
Preferred stock dividends - iBio CMO Preferred Tracking Stock 0 (66)
Net loss available to iBio, Inc. stockholders (7,537) (5,254)
Loss from discontinued operations (10,593) (3,751)
Net loss available to iBio, Inc. stockholders $ (18,130) $ (9,005)
Basic and diluted denominator:    
Weighted-average common shares outstanding - basic 8,842 8,715
Weighted-average common shares outstanding - diluted 8,842 8,715
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.85) $ (0.60)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.85) (0.60)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (1.20) (0.43)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (1.20) (0.43)
Per share amount basic (2.05) (1.03)
Per share amount diluted $ (2.05) $ (1.03)